Jun 8, 2026 · 7 min
Weight-loss drug bets reshape Lilly, Marvell and Campbell’s outlooks
Campbell's Edges Higher; Eli Lilly Gains; Marvell Rallies on S&P Addition
The episode contrasts breakthrough-driven market gains with the slower consumer shifts pressuring established packaged-food brands.
- 1Eli Lilly’s retatrutide growth has helped propel the company to a trillion-dollar market capitalization.
- 2Marvell Technology is set to join the S&P 500 after surging on an endorsement from Nvidia’s CEO.
- 3Campbell’s declining snack sales expose changing eating habits, despite strong performance from Rao’s.
Don't miss
Marvell Technology’s surge following an endorsement from Nvidia’s CEO stands out as the episode’s clearest market-moving moment.
The brief
Eli Lilly’s next-generation weight-loss drug, retatrutide, is driving impressive growth and has helped push the company to a trillion-dollar market cap.
Marvell Technology is preparing to join the S&P 500, while an endorsement from Nvidia’s CEO helped send its shares sharply higher.
Campbell’s faces a different market reality: snack sales are declining even as its Rao’s brand continues to perform strongly.
Together, the stocks show how drug innovation and technology enthusiasm can lift valuations while changing eating behavior weighs on packaged-food companies.
Featuring
Listen to the full episode and explore every guest, topic, and moment on PodLume.